MedTrace Logo

Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

NCT06349642 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 324

Last updated 2026-03-12

No results posted yet for this study

Summary

This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.

Conditions

  • Early Stage Triple-Negative Breast Carcinoma
  • Metastatic Bladder Urothelial Carcinoma
  • Metastatic Cervical Carcinoma
  • Metastatic Clear Cell Renal Cell Carcinoma
  • Metastatic Colorectal Carcinoma
  • Metastatic Endometrial Carcinoma
  • Metastatic Esophageal Carcinoma
  • Metastatic Liver Carcinoma
  • Metastatic Lung Non-Small Cell Carcinoma
  • Metastatic Malignant Skin Neoplasm
  • Metastatic Malignant Solid Neoplasm
  • Resectable Lung Non-Small Cell Carcinoma
  • Early Stage Lung Non-Small Cell Carcinoma
  • Resectable Malignant Solid Neoplasm
  • Resectable Triple-Negative Breast Carcinoma
  • Stage III Renal Cell Cancer AJCC v8
  • Stage IV Cervical Cancer AJCC v8
  • Stage IV Renal Cell Cancer AJCC v8
  • Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
  • Recurrent Cervical Carcinoma
  • Recurrent Colorectal Carcinoma
  • Recurrent Endometrial Carcinoma
  • Recurrent Esophageal Carcinoma
  • Recurrent Liver Carcinoma
  • Recurrent Lung Non-Small Cell Carcinoma
  • Recurrent Malignant Skin Neoplasm
  • Recurrent Malignant Solid Neoplasm

Interventions

PROCEDURE

Biospecimen Collection

Undergo optional research blood sample.

PROCEDURE

Tissue Collection

Tissue specimen collection will be completed with your scheduled standard of care biopsy if possible. If standard of care biopsy is already completed or the research biopsy wasn\'t collected at the time as your standard of care biopsy, then the research biopsy will be scheduled for a different day for research purposes only.

Sponsors & Collaborators

  • Elephas Biosciences Corporation

    collaborator UNKNOWN

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Dev Mukhopadhyay, PhD · Mayo Clinic

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-24
Primary Completion
2027-05-31
Completion
2027-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06349642 on ClinicalTrials.gov